Hyperion Biotechnology, Inc. — Federal Contractor Profile
HYPERION BIOTECHNOLOGY, INC. Secures $39.9M in Federal Contracts, Aiming for Diverse Client Base
Contractor Overview
Total Contract Value: $39,933,290 ($39.9M)
Total Awards: 6
Company Profile
HYPERION BIOTECHNOLOGY, INC. is a federal contractor with a total government contract value of $39.9 million, spanning six contracts with an average size of $6,655,548. The company has not won any recent contracts, indicating a potential shift in its business strategy or market conditions. Given the lack of sole-source contracts, it appears that the company has been successful in competing for government business. However, the absence of specific agency clients and recent contracts raises questions about the company's current focus and market presence. The company's core capabilities lie in biotechnology and related services, which are essential for various government agencies, particularly in research and development, medical support, and public health initiatives. The company's track record and notable projects are not detailed, but its consistent competitive wins suggest a strong market position. The company's business strategy seems to be centered on maintaining a diverse portfolio of contracts, which could mitigate risks associated with dependency on a single agency. However, the lack of recent contracts and the absence of specific agency clients indicate a need for further investigation into the company's current market position and future prospects.
Specializations
- Biotechnology
- Medical Research
- Public Health
- Pharmaceutical Development
- Genetic Engineering
- Biological Warfare Defense
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 100%
Agency Concentration: moderate
Growth Trajectory: stable
Sole Source Rate: 0%
Recompete Rate: 50%
Competitive Position
HYPERION BIOTECHNOLOGY, INC. appears to be a strong competitor in the biotechnology sector, with a consistent track record of winning competitive contracts. The company's focus on diverse capabilities and its ability to secure contracts across multiple agencies suggests a well-rounded business strategy. However, the lack of recent contracts and specific agency clients indicates that the company may be facing challenges in securing new business, which could impact its market position in the future.
Value to Taxpayers
HYPERION BIOTECHNOLOGY, INC. provides value to taxpayers through its biotechnology and medical research services, which are critical for advancing public health and medical knowledge. The company's competitive wins and diverse portfolio suggest that it is able to deliver high-quality services at reasonable costs. However, the absence of recent contracts and specific agency clients raises questions about the company's current market performance and future prospects, which could impact the value it provides to taxpayers.
Agency Relationships
The company's lack of specific agency clients and recent contracts indicates a need for further investigation into its current market position. While it has a diverse portfolio of contracts, the absence of recent wins and specific agency clients suggests that the company may be facing challenges in securing new business. This could pose a risk to the continuity of its services and the value it provides to taxpayers.
Red Flags
- Lack of recent contracts and specific agency clients, indicating potential challenges in securing new business.
- No sole-source contracts, which could suggest a reliance on competitive bidding processes that may be more challenging to win.
- Moderate agency concentration, which could indicate a risk of dependency on a few key clients.
Green Flags
- Consistent competitive wins, indicating a strong market position and ability to deliver high-quality services.
- Diverse portfolio of contracts across multiple agencies, which could mitigate risks associated with dependency on a single client.
- Focus on biotechnology and related services, which are critical for advancing public health and medical research.
Key Contracts
HYPERION BIOTECHNOLOGY, INC. has secured a total of six contracts with an average size of $6,655,548, totaling $39.9 million in government business. While the company has not won any recent contracts, its track record of competitive wins suggests a strong market position. The company's core capabilities in biotechnology and related services are essential for various government agencies, particularly in research and development, medical support, and public health initiatives. The lack of specific agency clients and recent contracts, however, raises questions about the company's current market performance and future prospects. The company's diverse portfolio of contracts across multiple agencies suggests a well-rounded business strategy, which could mitigate risks associated with dependency on a single client. However, the absence of recent wins and specific agency clients indicates a need for further investigation into the company's current market position and future prospects.
Frequently Asked Questions
What does HYPERION BIOTECHNOLOGY, INC. do for the federal government?
HYPERION BIOTECHNOLOGY, INC. specializes in biotechnology and related services, providing critical support for research and development, medical support, and public health initiatives. The company's core capabilities include medical research, pharmaceutical development, genetic engineering, and biological warfare defense. Its services are essential for advancing public health and medical knowledge, making it a valuable partner for various government agencies.
How much taxpayer money does HYPERION BIOTECHNOLOGY, INC. receive?
HYPERION BIOTECHNOLOGY, INC. has secured a total of $39.9 million in government contracts, with an average contract size of $6,655,548. The company has not won any recent contracts, indicating a potential shift in its business strategy or market conditions. The total contract value reflects the company's significant role in federal spending, with a diverse portfolio of contracts across multiple agencies.
Is HYPERION BIOTECHNOLOGY, INC. good value for taxpayer money?
HYPERION BIOTECHNOLOGY, INC. provides value to taxpayers through its biotechnology and medical research services, which are critical for advancing public health and medical knowledge. The company's competitive wins and diverse portfolio suggest that it is able to deliver high-quality services at reasonable costs. However, the absence of recent contracts and specific agency clients raises questions about the company's current market performance and future prospects, which could impact the value it provides to taxpayers.
How does HYPERION BIOTECHNOLOGY, INC. win its contracts?
HYPERION BIOTECHNOLOGY, INC. has a strong track record of winning competitive contracts, indicating a well-rounded business strategy. The company's focus on diverse capabilities and its ability to secure contracts across multiple agencies suggests that it is able to deliver high-quality services and meet the needs of various government agencies. However, the lack of recent contracts and specific agency clients indicates a need for further investigation into the company's current market position and future prospects.
What agencies use HYPERION BIOTECHNOLOGY, INC. most?
The company's lack of specific agency clients and recent contracts indicates a need for further investigation into its current market position. While it has a diverse portfolio of contracts across multiple agencies, the absence of recent wins and specific agency clients suggests that the company may be facing challenges in securing new business. This could pose a risk to the continuity of its services and the value it provides to taxpayers.
What are the risks of relying on HYPERION BIOTECHNOLOGY, INC.?
The risks of relying on HYPERION BIOTECHNOLOGY, INC. include potential challenges in securing new business, as indicated by the lack of recent contracts and specific agency clients. The company's moderate agency concentration could also pose a risk of dependency on a few key clients. However, the company's consistent competitive wins and diverse portfolio suggest that it is able to deliver high-quality services and mitigate some of these risks.
How does HYPERION BIOTECHNOLOGY, INC. compare to similar contractors?
HYPERION BIOTECHNOLOGY, INC. is a strong competitor in the biotechnology sector, with a consistent track record of winning competitive contracts. The company's focus on diverse capabilities and its ability to secure contracts across multiple agencies suggests a well-rounded business strategy. However, the lack of recent contracts and specific agency clients indicates a need for further investigation into the company's current market position and future prospects. Compared to similar contractors, HYPERION BIOTECHNOLOGY, INC. appears to be a strong player in the biotechnology sector, but its current market performance and future prospects are uncertain.
Recent Federal Contracts
Hyperion Biotechnology, Inc. has 3 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| Air Force personnel support contract awarded to Hyperion Biotechnology, Inc. ... | Department of Defense | $19.9M | N/A |
| VA awards $47.7K for Legionella water analysis, highlighting need for special... | Department of Veterans Affairs | $47.7K | N/A |
| VA awards $4.15M for Legionella Water Testing to Hyperion Biotechnology, Inc. | Department of Veterans Affairs | $41.5K | N/A |